Live feed08:01:00·18mPRReleasevia QuantisnowVoyager Demonstrates Single IV Dose of VY1706 Well Tolerated, Reduced Tau in 6-Month GLP Toxicology Study; Initiation of Clinical Trial in Alzheimer’s Disease Expected H2 2026ByQuantisnow·Wall Street's wire, on your screen.VYGR· Voyager Therapeutics Inc.Health Care
